{"title":"Lipids and hyperlipidaemia","authors":"F. Karpe","doi":"10.1093/med/9780198851899.003.0016","DOIUrl":null,"url":null,"abstract":"This chapter begins with lipids and coronary heart disease, and the assessment of CVD risk in the patient. It describes primary hyperlipidaemias, polygenic and familial hypercholesterolaemia, familial hypertriglyceridaemia, and rare genetic hypertriglyceridaemias. Elevation of Lp(a), rare familial mixed dyslipidaemias, secondary hyperlipidaemias, and drug therapy are all covered.","PeriodicalId":339875,"journal":{"name":"Oxford Handbook of Endocrinology & Diabetes 4e","volume":"120 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oxford Handbook of Endocrinology & Diabetes 4e","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/med/9780198851899.003.0016","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
This chapter begins with lipids and coronary heart disease, and the assessment of CVD risk in the patient. It describes primary hyperlipidaemias, polygenic and familial hypercholesterolaemia, familial hypertriglyceridaemia, and rare genetic hypertriglyceridaemias. Elevation of Lp(a), rare familial mixed dyslipidaemias, secondary hyperlipidaemias, and drug therapy are all covered.